HOOKIPA Pharma Inc. is a biotechnology company that develops immunotherapies and vaccine platforms, with collaborations in research and licensing, but specific financial and operational metrics are not disclosed.

# HOOKIPA Pharma Inc. Company Summary

**Overview:**
- HOOKIPA Pharma Inc. is a biotechnology company focused on developing immunotherapies, likely involving vaccine platforms and viral vector technologies.

**Corporate Details:**
- Jurisdiction: Delaware
- Principal Office: 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY 10118
- Telephone: +43 1 890 63 60
- Stock Symbol: HOOK (Nasdaq Capital Market)
- Ultimate parent: Not specified, but the company is publicly traded with a known market value (market cap as of June 30, 2024): approximately $57.0 million.
- Shares Outstanding (as of April 25, 2025): 9,782,872 shares of common stock; 2,399,517 shares of Class A common stock.

**Financial and Operational Data:**
- The company's financial details such as revenue, net income, or number of customers are **not provided** in the document.
- The document is a form 10-K/A (amended annual report) and mainly includes corporate governance, executive compensation, director info, and legal disclosures, but **does not specify specific financial metrics** like revenue, income, or customer count.

**Employees:**
- The number of employees is not directly stated.
- Key executives: 
  - CEO: Malte Peters
  - CFO: Terry Coelho
- Total employee count is not provided.

**Customers:**
- There are no details provided about the number of customers, clients, or partnerships besides Gilead Sciences, Inc., which is a significant shareholder and collaborator on research programs.

**Business Activities:**
- Engages in research collaborations, licensing agreements, and development of vaccine and immunotherapy technologies, including specific programs for HBV and HIV.
- Has licensed platforms and is involved in preclinical research, but specifics about product development status, clinical trials, or sales are not included.

**Summary:**
- HOOKIPA Pharma Inc. is a publicly traded biotech entity specializing in immunotherapeutic and vaccine platforms.
- It has strategic collaborations with large biopharmaceutical companies like Gilead.
- Specific operational metrics such as customer number, total revenue, net income, or employee count are not disclosed in the provided document.

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapeutics using a distinctive arenavirus platform.

# HOOKIPA Pharma Inc. Overview

## Company Profile
- **Name:** HOOKIPA Pharma Inc.
- **Incorporation:** Established as a corporation in the State of Delaware.
- **Location:** Principal executive offices in New York, NY; research and development operations in Vienna, Austria.
- **Ticker Symbol:** HOOK (traded on The Nasdaq Capital Market)

## Business Focus
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel immunotherapeutics using a proprietary arenavirus platform. This platform aims to enhance the immune response to combat infectious diseases and cancers by targeting T cells and amplifying adaptive immune responses.

## Technologies
- **Non-Replicating Technology:** Designed to induce strong immune responses for preventive and therapeutic use against infectious diseases.
- **Replicating Technology:** Engineered to elicit more robust immune responses, particularly in oncology, addressing cancer antigens to trigger potent CD8+ T cell responses.

## Product Pipeline
1. **Oncology Programs:**
   - **HB-200:** Phase 1/2 trial for HPV16+ head and neck cancers, presented positive preliminary data showing a 42% objective response rate in combination with pembrolizumab.
   - **HB-700:** Preclinical development for treating KRAS mutated cancers (lung, colorectal, pancreatic).
   - **HB-300:** Targeting prostate cancer; current development paused to conserve capital.

2. **Infectious Disease Programs:**
   - **HB-400:** Developed in partnership with Gilead for Hepatitis B, currently in Phase 1 trials.
   - **HB-500:** Developed with Gilead for HIV, FDA IND clearance received, Phase 1 trial expected to start in Q2 2024.

## Financial Information
- **Employees:** 151 full-time and 28 part-time employees (as of February 29, 2024).
- **Revenue:** As of December 31, 2023, specific revenue figures are not disclosed, but notable milestone achievements include:
  - $5 million milestone for HB-400 from Gilead.
  - $10 million milestone for HB-700 from Roche.
  - $50 million from a public offering in June 2023.
  - $21.25 million from a stock purchase agreement with Gilead in December 2023.
- **Net Income/Loss:** Significant losses reported - $64.9 million in 2022 and $81.6 million in 2023, accumulating a total deficit of $369.3 million.

## Market Position
- HOOKIPA Pharma operates in the highly competitive biopharmaceutical landscape. The company focuses on utilizing its innovative viral vector technology in immuno-oncology and infectious diseases. Their unique approach as a clinical-stage company with promising trial outcomes positions them as a participant in the exploration of new therapies against prevalent cancers and life-threatening infections.

## Strategic Partnerships
- Collaborations with major pharmaceutical companies like **Gilead Sciences** and **Roche** enhance research and development capabilities and expand their product pipeline.

---

This overview consolidates key information about HOOKIPA Pharma Inc., detailing its focus, technological approach, product pipeline, financial status, market position, and strategic partnerships. The company is currently navigating the challenges typical of clinical-stage biopharmaceuticals, with significant investments in R&D and a focus on innovative treatments to meet urgent medical needs.

HOOKIPA Pharma Inc.

10-K / April 30, 2025

10-K / March 22, 2024

10-K / April 30, 2025

HOOKIPA Pharma Inc. Company Summary